



**ASX ANNOUNCEMENT**

**3 September 2015**

## ***SeeThruEquity Initiates Cynata Research Coverage***

Cynata Therapeutics Ltd (ASX:CYP) announced today that SeeThruEquity, a leading US-based independent equity research and corporate access firm focused on smallcap and microcap public companies, has initiated equity analyst coverage with the release of a new report on Cynata.

The full SeeThruEquity report can be viewed on Cynata's website at [www.cynata.com](http://www.cynata.com).

### **CONTACTS:**

Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)  
Amit Tandon, Director of Research, SeeThruEquity: +1 (646) 495-0939; [amit@seethruequity.com](mailto:amit@seethruequity.com)  
Kirin Smith, Chief Operations Officer, US Investor Contact, + 1 646-863-6519, [ksmith@pcgadvisory.com](mailto:ksmith@pcgadvisory.com)  
Sean Leous, Chief Communications Officer, US Media Contact, +1 646-863-8998, [sleous@pcgadvisory.com](mailto:sleous@pcgadvisory.com)  
Emma Power, Monsoon Communications, Australia Media Contact, 0419 149 525, [emmap@monsoon.com.au](mailto:emmap@monsoon.com.au)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.